ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / SDGR / news
MRVI (37) ZYME (50) SEPN (63) SRPT (27) ⌘ Pro Terminal →

Why SDGR Stock dropped -3.50% Today — RQD Quant Desk Flash

$26.19 -3.50% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $25.98

Schrodinger Inc. (SDGR) carries a Roarable Rating of D+ (Sell) with 53/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $2.03B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SDGR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SDGR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Schrodinger Inc. (NASDAQ: SDGR) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $26.19 (-3.50% 1D, market cap $2.03B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, SDGR ranks #230 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SDGR compare to MRVI and ZYME in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SDGR carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of 55.7%, and ROIC of -35.0%. By comparison, MRVI (Maravai LifeSciences Holdings Inc. (Class A)) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $2.03B) and ZYME (Zymeworks Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -32.2%, cap $2.02B). Among the 5-stock peer group, SDGR leads on earnings multiple (N/A) while SEPN leads on capital efficiency (-20.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SDGR?
▼

Per SDGR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001490978), Schrodinger Inc. generated $255.9M in revenue (+23.3% YoY), -$103.3M in net income, and $12.5M in free cash flow against $726.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $25.98 (-0.82%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 4.9% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 53/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.9% avg 90D alpha vs SPY • 50.6% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510053
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk D+
Cash (11)Whales (14)SEC (12)Macro (10)CEO (6)
Each axis scored 0–20
12M PRICE TARGET CONE-2.3% Base Target
$35 Bull$26 Base$20 Bear
📬 FREE SDGR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SDGR)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (53/100 Composite)
🔍 WHY SDGR SCORES 53/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (26% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+12/20 pts (23% of score)

Altman Z-Score 2.64 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution6/20 pts (-14 pt drag)

Dilution Drag (+1.64% YoY Shares) & executive Form 4 sales trim 14 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
45
Grade D$25.89-9.6% Next Q
Q2 (-2Q)
48
Grade D$23.40+14.2% Next Q
Q3 (-1Q)
50
Grade C-$26.72-2% Next Q
Current
53
Grade D+$26.19-0.9% Hist 90D α
Trajectory: D (45) → D+ (53)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SDGR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SDGR currently carries a cautious 53/100 (D+) rating due to Insider Conviction & Share Dilution (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($25.33) and Max Pain ($27.50) forces dealer call-delta covering toward $35.47.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SDGR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SDGR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 53%NO 47%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why SDGR Stock dropped -3.50% Today — RQD Quant Desk Flash

Schrodinger Inc. (SDGR) dropped -3.50% to $26.19, trading at 67% of its 52-week range ($10.94 – $33.78). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 67% of its 52-week range ($10.94 – $33.78) with RSI-14 at 51.8 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $26.19 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D+ (Sell) backed by 55.7% gross margin and $12.5M annual free cash flow.
Live SDGR Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SDGR)

  • ✓Walkthrough of SDGR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
SDGR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +103.02%▲ ASCENDING CHANNEL
2026-11-03O $29.99H $29.99L $26.19C $26.19VOL 1.95M
RES: $37.70SUP: $19.12SMA50: $25.33SMA200: $16.87
$35.34$28.89$22.45$16.00$9.56RES $37.70SUP $19.12$26.192026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SDGR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SDGR Butterfly Map → + Track SDGR →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +23.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SDGR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SDGR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SDGR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SDGR)

Health Care Rank #230 of 1015 ⚔️ MRVI vs SDGR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SDGR vs. MRVI, ZYME, SEPN, SRPT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Schrodinger Inc. (SDGR) ranks #230 by composite RQD confidence (53/100, grade D+) and #251 by equity capitalization ($2.03B). Within this direct 5-issuer industry benchmark cohort, SDGR leads on earnings valuation at N/A trailing P/E, while SEPN leads on capital efficiency and profitability with -20.7% ROIC and — gross margin. SEPN currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with SDGR at 53/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SDGR ACTIVE
Schrodinger Inc.
D+ 53/100 — 55.7% -35.0% -3.50% $2.03B Benchmark Subject
MRVI
Maravai LifeSciences Holdings Inc. (Class A)
D- 37/100 — 18.3% -35.0% -7.94% $2.03B /mrvi-vs-sdgr →
ZYME
Zymeworks Inc.
D 50/100 — — -32.2% +1.33% $2.02B /zyme-vs-sdgr →
SEPN
Septerna Inc.
C 63/100 — — -20.7% -1.82% $2.05B /sepn-vs-sdgr →
SRPT
Sarepta Therapeutics Inc.
E 27/100 — 96.0% -35.0% -1.61% $1.97B /srpt-vs-sdgr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001490978 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Schrodinger Inc. (SDGR) reported GAAP revenue of $255.9M (+23.3% vs. FY2024 revenue of $207.5M , and +18.1% cumulative change since FY2023) , GAAP net income of -$103.3M, operating cash flow of $13.9M, and free cash flow of $12.5M (+107.6% YoY). On the balance sheet, SDGR closed FY2025 with $726.2M in total assets against $0 in total debt (Altman Z-Score: 2.64, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $255.9M -$103.3M $13.9M $12.5M $726.2M —
FY2024 (FY) 2024-12-31 $207.5M -$187.1M -$157.4M -$164.7M $823.2M —
FY2023 (FY) 2023-12-31 $216.7M $40.7M -$136.7M -$136.7M — —

3. SDGR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SDGR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Schrodinger Inc. (NASDAQ: SDGR) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $26.19 (-3.50% 1D, market cap $2.03B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, SDGR ranks #230 in composite RQD confidence.

How does SDGR compare to MRVI and ZYME in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SDGR carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of 55.7%, and ROIC of -35.0%. By comparison, MRVI (Maravai LifeSciences Holdings Inc. (Class A)) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $2.03B) and ZYME (Zymeworks Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -32.2%, cap $2.02B). Among the 5-stock peer group, SDGR leads on earnings multiple (N/A) while SEPN leads on capital efficiency (-20.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SDGR?

Per SDGR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001490978), Schrodinger Inc. generated $255.9M in revenue (+23.3% YoY), -$103.3M in net income, and $12.5M in free cash flow against $726.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SDGR trading relative to its 50-day, 200-day, and 52-week technical levels?

SDGR last traded at $26.19 (-3.50% on volume of 1,392,057 shares), positioning the stock +3.40% above its 50-day simple moving average ($25.33) and +55.25% above its 200-day simple moving average ($16.87). Across its 52-week range of $10.94 to $33.78, SDGR sits at the 66.8% percentile with a 14-day RSI of 51.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($22.92 to $29.46).

Direct Sub-Reports: SDGR RQD Cockpit SDGR 12M Forecast SDGR Earnings & Move SDGR Dividends & DRIP SDGR Insiders & 13F SDGR Whale Options SDGR Profit Sankey SDGR News & Why
ROARABLE RATING BRIEF • RQD 53/100 (D+) ✓ SEC XBRL & RQD VERIFIED

SDGR — Schrodinger Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Schrodinger Inc. (SDGR) earns a live Roarable RQD composite score of 53/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $26.19 (-3.50% 1D, market capitalization $2.03B).

  • Fundamental Cash Engine (11/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 55.7%, operating margin of -60.0%, and free cash flow yield of 0.56%.
  • Whale 13F & Options Flow (14/20) + Insider Conviction (6/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (12/20): Incorporates a 1.00x equity beta, Altman Z-Score of 2.64, Piotroski F-Score of 7/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Schrodinger Inc. Is a NASDAQ-listed issuer classified under the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. Its market capitalization is $2.2B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Schrodinger Inc. (SDGR) reported $255.9M in annual revenue (up from $207.5M in FY2024, +23.3% YoY) and -$103.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($216.7M revenue, $40.7M net income) through FY2025, SDGR scaled operating cash flow to $13.9M and free cash flow to $12.5M, backed by $726.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D+ • RQD 53/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 0.56% and institutional whale pillar of 14/20. With Fundamental Cash Engine at 11/20 and Institutional Whale Flow at 14/20, sustained execution supports upside toward the upper end of the $10.94 – $33.78 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the provided source data. — for detailed ripple analysis beyond sector classification (Health Care, Biotechnology: Pharmaceutical Preparations).

  • Key Question #1: Can SDGR sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $255.9M and free cash flow of $12.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is SDGR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SDGR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Schrodinger Inc. (SDGR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SDGR Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SDGR Bull vs. Bear Conversation Board — What's Your Call at $26.19?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SDGR 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SDGR:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $34.20 (+26.0%)
📌 Pinned Debate

Institutional whale-flow score of 17/20 and a forensic balance sheet with Piotroski F 7/9 and Altman Z 2.64 signal underlying accumulat

Long SDGR at $27.14 targeting $34.20. Institutional whale-flow score of 17/20 and a forensic balance sheet with Piotroski F 7/9 and Altman Z 2.64 signal underlying accumulation and financial stability.. Institutional whale score is 14/20 and the risk/reward vs. the $10.94 52-week low is skewed heavily in favor of bulls.

ArenaChamp_24 🐂 BULL

@QuantViper Agree on the RQD 53/100 quality, though with 1.0 beta I'm scaling in with half-size at $27.14 and keeping dry powder in case we test $25.24.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $22.80 (-16.0%)
Spot @ $27.14

ROIC of -35%, operating margin of -60%, and a 0.56% FCF yield show the business is not currently generating returns on its capital.

Here is the bear case nobody on the bull side wants to address on SDGR: ROIC of -35%, operating margin of -60%, and a 0.56% FCF yield show the business is not currently generating returns on its capital.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%